1
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: Intermediates useful for making 2,4-pyrimidinediamine compounds. Rigel Pharmaceuticals, Dechert, June 13, 2006: US07060827 (128 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


2
Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim: Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds. Rigel Pharmaceuticals, Dechert, October 17, 2006: US07122542 (125 worldwide citation)

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with ...


3
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, Brian D Griedel, February 19, 2008: US07332484 (79 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


4
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, July 7, 2009: US07557210 (76 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


5
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, Brian D Griedel, February 12, 2008: US07329671 (76 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


6
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, Brian D Griedel, February 12, 2008: US07329672 (70 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


7
Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim: Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, November 18, 2008: US07452879 (68 worldwide citation)

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with ...


8
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-pyrimidinediamine compounds and their uses. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, February 3, 2009: US07485724 (67 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...


9
Rajinder Singh, Ankush Argade, Donald G Payan, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li: Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds. Rigel Pharmaceuticals, Foley & Lardner, James J Diehl, April 14, 2009: US07517886 (64 worldwide citation)

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with ...


10
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi: 2,4-Pyrimidinediamine compounds and their uses. Rogel Pharmaceuticals, Swiss Tanner P C, January 5, 2010: US07642351 (60 worldwide citation)

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in ...